News & Events

Check out our news section to keep up to date with any upcoming events which we will be attending as well as any exciting news within the pharmaceutical industry.

SUCCESSFUL MHRA REGULATORY INSPECTION FOR SYMBIOSIS

RAPIDLY-GROWING contract manufacturing organisation (CMO) Symbiosis Pharmaceutical Services (Symbiosis), has successfully completed a scheduled inspection by the UK Government regulator, the Medicines and Healthcare products Regulatory Agency (MHRA).Headquartered in Stirling, UK, and specialising in the sterile manufacture of vaccines, pharmaceuticals and biopharmaceuticals for clinical and commercial use, Symbiosis recorded no critical or major observations from the reinspection by the MHRA.In order to… Read More

Life Sciences Innovation and Responding to COVID-19

Scotland’s Minister for Trade, Investment and Innovation, Ivan McKee recently issued a statement to the Scottish Parliament regarding the COVID-19 crisis and Scotland’s life science sector’s support for and response to the COVID-19 pandemic.The accompanying report sets out the work of the sector including examples across test supply chain, vaccine development and repurposing of drugs and aims to provide a snapshot of… Read More

Symbiosis confirms commitment to growth strategy with key appointment

Symbiosis Pharmaceutical Services (Symbiosis), a fast-growing contract manufacturing organisation (CMO) specialising in sterile manufacture of vaccines, pharmaceuticals and biopharmaceuticals, and headquartered in Stirling, UK, has appointed Mr. John McCormick as Chief Operating Officer (COO) and executive member of its Board of Directors.Previously operations development director at Symbiosis, Mr. McCormick has 15 years of experience in the pharmaceutical and biotechnology industry in various… Read More

Symbiosis secures £1 million of growth finance from Allied Irish Bank (GB)

Stirling-based Symbiosis Pharmaceutical Services has secured £1million of finance from Allied Irish Bank (GB) to support its 2020 growth strategy.Symbiosis provides niche, sterile manufacturing services to global biotechnology and pharmaceutical company clients that are developing novel drug therapies and vaccines for use in clinical trials or the commercial market.Symbiosis’s facility at Stirling Innovation Park was purpose built in 2011 to manufacture deliberately… Read More

Symbiosis and AstraZeneca Sign Supply Agreement for Sterile Manufacture of COVID-19 Vaccine for Clinical Trials

Stirling, UK: Symbiosis Pharmaceutical Services, a specialist provider of pharmaceutical and vaccine development services, has announced it has signed a supply agreement with AstraZeneca for sterile manufacture of the COVID-19 recombinant adenovirus vaccine known as AZD1222 for AstraZeneca sponsored clinical trials.Under the agreement, Symbiosis will provide AstraZeneca fast-track access to sterile vaccine drug product manufacturing capacity for clinical trial supply.The agreement follows… Read More

Race for the vaccine

We think this is a great overview and general summary of the challenges and process of making a new drug in relation to the current coronavirus crisis:On 16 March, a needle was put in the arm of a Seattle woman who may change the world.Jennifer Haller had a candidate vaccine against coronavirus injected into her bloodstream – the first human trial aimed… Read More

COVID-19 vaccine & therapy research boosted by six new projects in rapid response

Six new studies into the novel coronavirus have been funded by the UK government, including testing a vaccine, developing therapies and improving understanding of how to treat COVID-19.This first round of projects receive £10.5 million as part of the £20 million rapid research response funded by UK Research and Innovation (UKRI), and by the Department of Health and Social Care through the… Read More

Q&A: Cell and gene processing moves forward through ‘experiential learning’

Colin MacKay, CEO of Symbiosis Pharmaceutical Services, recently took part in a Q&A interview with BioPharma-Reporter, discussing how increased manufacturing demand for cell and gene therapies is driving the growth of the viral vector supply market and the challenges that are still to be addressed.The growing prevalence of cell and gene therapies in both the clinical and the commercial side of the… Read More

Symbiosis invests £1.5 million in UK facility expansion

Stirling, UK – Fast-growing specialist sterile manufacturing and Contract Manufacturing Organisation (CMO) Symbiosis Pharmaceutical Services (Symbiosis), has expanded its sterile biologics manufacturing facility in Scotland, UK by 25%.In the last 12 months Symbiosis has invested over £1.5m ($1.9m) in the expansion of its Stirling site, doubling its current footprint with an additional 8,000 sq ft of office space to house the firm’s… Read More

Cobra Biologics and Symbiosis Complete £4.8m Viral Vector Supply Chain Collaboration

Keele and Stirling, UK – Cobra Biologics (Cobra), an international contract development and manufacturing organisation (CDMO) focused on viral vector drug substance production, and Symbiosis Pharmaceutical Services (Symbiosis), a contract manufacturing organisation (CMO) specialising in the sterile manufacture of injectable viral vector drug products, today announced the successful completion of their collaboration to develop synergistic and world leading capabilities.Intended to accelerate the clinical… Read More

Get In Touch.


By ticking the box and clicking “Submit” below, you consent to receiving thought leadership, industry news, and invitations by email or other electronic means, which Symbiosis Pharmaceutical Services believes may be of value to you, relevant to your work and tailored to your professional profile and interests. This may include promotional information on products, services and events provided or organised by Symbiosis Pharmaceutical Services. By clicking the "Submit” button, you confirm that the information you have provided above is correct, and you agree to Symbiosis' processing of your personal data, including its transfer internationally and to third parties, in accordance with it's privacy policy.